2015
Predictors of antiretroviral therapy initiation: a cross-sectional study among Chinese HIV-infected men who have sex with men
Liu Y, Ruan Y, Vermund SH, Osborn CY, Wu P, Jia Y, Shao Y, Qian HZ. Predictors of antiretroviral therapy initiation: a cross-sectional study among Chinese HIV-infected men who have sex with men. BMC Infectious Diseases 2015, 15: 570. PMID: 26714889, PMCID: PMC4696158, DOI: 10.1186/s12879-015-1309-x.Peer-Reviewed Original ResearchConceptsCells/μLAntiretroviral therapy initiationART initiationHIV infectionCross-sectional studyTherapy initiationChinese MSMWorld Health Organization (WHO) clinical stage III/IVClinical stage III/IVStage III/IVNational HIV treatment guidelinesCD4 cell countHIV treatment guidelinesHIV viral suppressionLonger durationLogistic regression modelsChinese HIVEligible HIVCD4 countHIV careViral suppressionART eligibilityMedian durationTreatment guidelinesClinical symptoms
2009
Assessing yellow fever risk in the Ecuadorian Amazon
Izurieta RO, Macaluso M, Watts DM, Tesh RB, Guerra B, Cruz LM, Galwankar S, Vermund SH. Assessing yellow fever risk in the Ecuadorian Amazon. Journal Of Global Infectious Diseases 2009, 1: 7-13. PMID: 20300380, PMCID: PMC2840941, DOI: 10.4103/0974-777x.49188.Peer-Reviewed Original ResearchYellow fever casesYellow fever infectionFever infectionFever casesSerum glutamic oxaloacetic transaminaseSerum glutamic pyruvicHumoral immune responseCross-sectional studyDengue-2 infectionsIgG-specific antibodiesGlutamic oxaloacetic transaminaseYellow fever outbreaksYellow fever riskMilitary personnelSeroepidemiological methodsClinical symptomsRisk factorsImmune responseOxaloacetic transaminaseGlutamic pyruvicFever riskFever outbreakAttack rateSpecific antibodiesYellow fever
1992
The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection
Graham N, Zeger S, Park L, Vermund S, Detels R, Rinaldo C, Phair J. The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 326: 1037-1042. PMID: 1347907, DOI: 10.1056/nejm199204163261601.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSPneumocystis carinii pneumoniaPCP prophylaxisProlong survivalEarly treatmentRelative riskVirus infectionCell countUse of zidovudineUse of prophylaxisDiagnosis of AIDSHIV Type 1HIV-1 infectionBasis of CD4High-risk menInitial disease stateProbability of deathZidovudine usersZidovudine therapyImmunodeficiency syndromeCarinii pneumoniaClinical symptomsProphylaxis